These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17113639)

  • 1. Match unrelated bone marrow transplantation in a case of high risk myelodysplastic syndrome treated with azacitidine and concomitant 1alpha-25-dihydroxyvitamin D3, as differentiating agent.
    Orciuolo E; Cecconi N; Galimberti S; Papineschi F; Petrini M
    Leuk Res; 2007 Sep; 31(9):1321-3. PubMed ID: 17113639
    [No Abstract]   [Full Text] [Related]  

  • 2. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
    Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
    Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
    Suwanawiboon B; Sumida KN
    Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitine (vidaza) for myelodysplastic syndrome.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
    Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
    Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous azacitidine for MDS.
    Gore SD
    Clin Adv Hematol Oncol; 2007 Mar; 5(3):234. PubMed ID: 17519884
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful allogeneic stem-cell transplantation in a patient with myelodysplastic syndrome with hemodialysis-dependent end-stage renal disease.
    Choi HS; Kim SY; Lee JH; Yoon SY; Cho YH; Lee HG
    Transplantation; 2011 Sep; 92(6):e28-9. PubMed ID: 21909016
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
    Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
    Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 11. MDS: navigating the complex course.
    Fortenbaugh C
    ONS News; 2006; 21(8 Suppl):17-8. PubMed ID: 16925134
    [No Abstract]   [Full Text] [Related]  

  • 12. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
    Fenaux P; Bowen D; Gattermann N; Hellström-Lindberg E; Hofmann WK; Pfeilstöcker M; Sanz G; Santini V
    Leuk Res; 2010 Nov; 34(11):1410-6. PubMed ID: 20609474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preface. The biology and treatment of myelodysplastic syndrome.
    Ebert BL
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):xiii-xvi. PubMed ID: 20359625
    [No Abstract]   [Full Text] [Related]  

  • 14. [Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelodysplastic syndrome].
    Maeda Y
    Rinsho Ketsueki; 2014 Oct; 55(10):1870-81. PubMed ID: 25297751
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.
    D'Alò F; Leone G; Hohaus S; Teofili L; Bozzoli V; Tisi MC; Rufini V; Calcagni ML; Voso MT
    Br J Haematol; 2011 Jul; 154(1):141-3. PubMed ID: 21332703
    [No Abstract]   [Full Text] [Related]  

  • 16. Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.
    Della Porta MG; Alessandrino EP
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1260-1. PubMed ID: 25020100
    [No Abstract]   [Full Text] [Related]  

  • 17. Transplantation for MDS in the elderly: more evidence, or more bias?
    Cutler C
    Biol Blood Marrow Transplant; 2012 Sep; 18(9):1320-1. PubMed ID: 22750646
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndromes.
    Carella AM
    Eur J Haematol; 2015 Jun; 94(6):463. PubMed ID: 25702976
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone marrow leukaemic transformation of myelodysplastic syndrome revealed by a cutaneous Langerhans cell infiltrate: partial response to azacitidine.
    Osio A; Elfatoiki F; Raffoux E; Vignon-Pennamen MD; de Labarthe A; Cordoliani F; Petrella T; Bagot M; Janin A; Battistella M; Bouaziz JD
    Eur J Dermatol; 2013; 23(5):710-1. PubMed ID: 24125873
    [No Abstract]   [Full Text] [Related]  

  • 20. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
    Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
    Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.